Lupin Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each fully paid up for the Financial Year ended March 31, 2026.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited reported strong FY2026 results with consolidated revenue growing 23% to ₹279.6 billion from ₹227.1 billion. Profit after tax surged 62% to ₹53.6 billion on consolidated basis and 60% to ₹63.7 billion on standalone basis. The Board recommended a dividend of ₹18 per share (900% of face value), up from previous years. Key exceptional items included ₹5.8 billion cumulative provision for antitrust litigation, ₹8.5 billion settlement with Astellas for Mirabegron ER tablets, and ₹512 million for new labour codes implementation. The company completed acquisitions of VISUfarma B.V. (€192.8 million) and Renascience Pharma UK during the year. Auditor B S R & Co. LLP issued an unmodified opinion, confirming clean financials.
Strong profitability growth and clean audit opinion are positive signals for shareholders. The significant 23% revenue growth and 60%+ PAT growth demonstrate operational strength, though exceptional litigation items and settlements create some one-time noise in earnings.